Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02186873
Registration number
NCT02186873
Ethics application status
Date submitted
8/07/2014
Date registered
10/07/2014
Date last updated
22/12/2017
Titles & IDs
Public title
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
Query!
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis
Query!
Secondary ID [1]
0
0
CNTO148AKS3001
Query!
Secondary ID [2]
0
0
CR103795
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ankylosing Spondylitis
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Golimumab
Experimental: Treatment Group 1: Placebo then Golimumab - Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
Experimental: Treatment Group 2: Golimumab - Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
Treatment: Drugs: Placebo
Participants will receive matching placebo.
Treatment: Drugs: Golimumab
Participants will receive 2mg/kg of intravenous infusions of golimumab .
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieved at Least 20 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 20) at Week 16
Query!
Assessment method [1]
0
0
ASAS 20 defined as 20 percent (%) improvement compared to baseline in the ASAS Working Group criteria: that is, greater than or equal to (>=)20% improvement from baseline in at least 3 of the 4 domains: patient's global assessment of disease activity (0=very well,10 =very poor), total back pain (0=no pain,10=most severe pain), function (self-assessment using BASFI [0=no functional impairment to 10= maximal impairment]), inflammation (0=none,10=very severe) with an absolute improvement of at least 1 (0-10 centimeter (cm) visual analogue scale [VAS]), and an absence of deterioration (defined as >=20% worsening and absolute worsening of at least 1 on a 0-10 cm scale) in the potential remaining domain.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieved at Least 40 Percent Improvement From Baseline in the Assessment of SpondyloArthritis International Society (ASAS 40) at Week 16
Query!
Assessment method [1]
0
0
An ASAS 40 response is defined as >=40% improvement from baseline in 3 of 4 domains: patient's global assessment of disease activity (0=very well, 10=very poor), total back pain (0=no pain, 10=most severe pain), function (self-assessment using BASFI (0=no functional impairment to 10=maximal impairment), inflammation (0=none, 10=very severe) with an absolute improvement of at least 2 (0-10 cm VAS), and no deterioration in the remaining domain.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieved at Least 50 Percent Improvement From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 16
Query!
Assessment method [2]
0
0
The BASDAI is a self-assessment tool to determine disease activity using a VAS of 0-10 cm (0=none and 10=very severe) participant's answered 6 questions measuring fatigue, spinal pain, joint pain, enthesitis, and morning stiffness. The final BASDAI is calculated as a mean of individual questions with a final score range of 0 to 10 cm; 0=best and 10=worst.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [3]
0
0
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score at Week 16
Query!
Assessment method [3]
0
0
The BASFI is a participant's self-assessment of physical function represented as a mean of 10 questions, each question rated on VAS 0 to 10 cm (VAS 0 to 10 cm; 0=easy to 10=impossible), 8 of which relate to the participant's functional anatomy and 2 of which relate to a participant's ability to cope with everyday life.
Query!
Timepoint [3]
0
0
Baseline and Week 16
Query!
Secondary outcome [4]
0
0
Change From Baseline in Short Form-36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16
Query!
Assessment method [4]
0
0
The Medical Outcome Study health measure SF-36 questionnaire is a well-validated and widely used quality-of-life instrument. It is a self-administered survey that consists of 8 multi-item scales: The 4 subscales of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and the 4 subscales of the SF-36 comprises the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health (worst value is 0 and best value is 100), which are scored using a norm-based system where linear transformations are performed to transform scores to a mean of 50 and standard deviation of 10.
Query!
Timepoint [4]
0
0
Baseline and Week 16
Query!
Secondary outcome [5]
0
0
Change From Baseline in Short Form-36 Health Survey (SF-36) Mental Component Summary (MCS) Score at Week 16
Query!
Assessment method [5]
0
0
The Medical Outcome Study health measure SF-36 questionnaire is a well-validated and widely used quality-of-life instrument. It is a self-administered survey that consists of 8 multi-item scales: The 4 subscales of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and the 4 subscales of the SF-36 comprises the MCS score(vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health (worst value is 0 and best value is 100), which are scored using a norm-based system where linear transformations are performed to transform scores to a mean of 50 and standard deviation of 10.
Query!
Timepoint [5]
0
0
Baseline and Week 16
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Low Level of Disease Activity (ASAS Partial Remission) at Week 16
Query!
Assessment method [6]
0
0
Low level of disease activity was measured by criteria for ASAS partial remission, defined as a value below 2 on a scale of 0 to 10 cm in each of the 4 ASAS domains: patient's global assessment of disease activity, total back pain, function (BASFI), inflammation.
Query!
Timepoint [6]
0
0
Week 16
Query!
Secondary outcome [7]
0
0
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 16
Query!
Assessment method [7]
0
0
The ASQoL is a self-administered health-related quality of life (HRQOL) instrument. It consists of 18 items requesting a Yes or No response to questions related to the impact of the disease/condition (including pain) on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. A score of 1 is given to a response of "yes" on each item and all item scores are summed to a total score with a range of 0 to 18. Higher scores indicate worse HRQOL.
Query!
Timepoint [7]
0
0
Baseline and Week 16
Query!
Secondary outcome [8]
0
0
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 16
Query!
Assessment method [8]
0
0
BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: tragus to wall distance, lumbar flexion, cervical rotation, lumbar side flexion, and intermalleolar distance. Each measure was scored 0-2 (0=normal mobility/mild disease involvement, 1=moderate disease involvement, 2=severe disease involvement) to give a final total BASMI score ranging from 0 to 10. The higher the BASMI score, the more severe was the participant's limitation of movement due to their AS.
Query!
Timepoint [8]
0
0
Baseline and Week 16
Query!
Eligibility
Key inclusion criteria
- Participants with diagnosis of definite ankylosing spondylitis for at least 3 months
based on modified New York radiographic and clinical criteria
- Participants with symptoms of active disease at screening and at baseline
- Participant has either an inadequate response to at least 2 non-steroidal
anti-inflammatory drugs (NSAID) over a 4 week period in total with maximal recommended
doses of NSAIDs, or is unable to receive a full 4 weeks of maximal NSAID therapy
because of intolerance, toxicity, or contraindications to NSAIDs
- Participants with C- reactive protein (CRP) level of greater than or equal to (>=) 0.3
milligram per deciliter (mg/dL) at screening
- Additional protocol-defined inclusion criteria apply
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Participant with other inflammatory diseases that might confound the evaluations of
benefit from the golimumab therapy
- Pregnant or lactating females
- Participants with chest radiograph within 3 months prior to the first administration
of study agent that shows an abnormality suggestive of a malignancy or current active
infection, including tuberculosis
- Participants who had a serious infection (including but not limited to, hepatitis,
pneumonia, sepsis, or pyelonephritis), or have been hospitalized for an infection, or
have been treated with intravenous (IV) antibiotics for an infection within 2 months
prior to first administration of study agent
- Additional protocol-defined exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/09/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/10/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
208
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Maroochydore
Query!
Recruitment postcode(s) [1]
0
0
- Maroochydore
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Indiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Ohio
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Newfoundland and Labrador
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Burlington
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Trois-Rivieres
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Bad Doberan
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Berlin
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Erfurt
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Hamburg
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Planegg
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Ratingen
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Zerbst
Query!
Country [20]
0
0
Korea, Republic of
Query!
State/province [20]
0
0
Ansan
Query!
Country [21]
0
0
Korea, Republic of
Query!
State/province [21]
0
0
Daegu
Query!
Country [22]
0
0
Korea, Republic of
Query!
State/province [22]
0
0
Gwangju
Query!
Country [23]
0
0
Korea, Republic of
Query!
State/province [23]
0
0
Seongdong-Gu
Query!
Country [24]
0
0
Korea, Republic of
Query!
State/province [24]
0
0
Seoul
Query!
Country [25]
0
0
Mexico
Query!
State/province [25]
0
0
Chihuahua
Query!
Country [26]
0
0
Poland
Query!
State/province [26]
0
0
Bydgoszcz
Query!
Country [27]
0
0
Poland
Query!
State/province [27]
0
0
Bytom
Query!
Country [28]
0
0
Poland
Query!
State/province [28]
0
0
Nadarzyn
Query!
Country [29]
0
0
Poland
Query!
State/province [29]
0
0
Nowa Sól
Query!
Country [30]
0
0
Poland
Query!
State/province [30]
0
0
Poznan
Query!
Country [31]
0
0
Poland
Query!
State/province [31]
0
0
Warszawa
Query!
Country [32]
0
0
Russian Federation
Query!
State/province [32]
0
0
Moscow
Query!
Country [33]
0
0
Russian Federation
Query!
State/province [33]
0
0
Saint Petersburg
Query!
Country [34]
0
0
Russian Federation
Query!
State/province [34]
0
0
Saint-Petersburg
Query!
Country [35]
0
0
Russian Federation
Query!
State/province [35]
0
0
Saratov
Query!
Country [36]
0
0
Russian Federation
Query!
State/province [36]
0
0
Smolensk
Query!
Country [37]
0
0
Russian Federation
Query!
State/province [37]
0
0
Tver
Query!
Country [38]
0
0
Ukraine
Query!
State/province [38]
0
0
Chernihiv
Query!
Country [39]
0
0
Ukraine
Query!
State/province [39]
0
0
Dnipropetrovsk
Query!
Country [40]
0
0
Ukraine
Query!
State/province [40]
0
0
Kyiv
Query!
Country [41]
0
0
Ukraine
Query!
State/province [41]
0
0
Odessa
Query!
Country [42]
0
0
Ukraine
Query!
State/province [42]
0
0
Vinnytsia
Query!
Country [43]
0
0
Ukraine
Query!
State/province [43]
0
0
Zaporizhzhia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy of intravenously (administration of a
fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants
with active ankylosing spondylitis (chronic inflammatory disease of unknown etiology that
involves the sacroiliac joints, and often the axial skeleton, entheses, and peripheral
joints).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02186873
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02186873
Download to PDF